SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • Abbracchio MP, Brambilla R, Ceruti S, Kim HO, von Lubitz DK, Jacobson KA, Cattabeni F. 1995. G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol 48: 10381045.
  • Abbracchio MP, Camurri A, Ceruti S, Cattabeni F, Falzano L, Giammarioli AM, Jacobson KA, Trincavelli L, Martini C, Malorni W, Fiorentini C. 2001. The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. Ann NY Acad Sci 939: 6373.
  • Ali H, Cunha-Melo JR, Saul WF, Beaven MA. 1990. Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor. J Biol Chem 265: 745753.
  • Aoyama S, Kase H, Borrelli E. 2000. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 20: 58485852.
  • Armstrong S, Ganote CE. 1994. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: Evidence of A3 receptor involvement. Cardiovasc Res 28: 10491056.
  • Armstrong S, Ganote CE. 1995. In vitro ischaemic preconditioning of isolated rabbit cardiomyocytes: Effects of selective adenosine receptor blockade and calphostin C. Cardiovasc Res 29: 647652.
  • Armstrong JM, Chen JF, Schwarzschild MA, Apasov S, Smith PT, Caldwell C, Chen P, Figler H, Sullivan G, Fink S, Linden J, Sitkovsky M. 2001. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: Studies of cells from A2A-receptor-gene-deficient mice. Biochem J 354(Pt. 1): 123130.
  • Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC. 2001. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50: 5663.
  • Atkinson MR, Townsend-Nicholson A, Nicholl JK, Sutherland GR, Schofield PR. 1997. Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene. Neurosci Res 29: 7379.
  • Auchampach JA, Jin X, Wan TC, Caughey GH, Linden J. 1997a. Canine mast cell adenosine receptors: Cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mol Pharmacol 52: 846860.
  • Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, Bolli R. 1997b. Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 80: 800809.
  • Bailey A, Ledent C, Kelly M, Hourani SM, Kitchen I. 2002. Changes in spinal delta and kappa opioid systems in mice deficient in the A2A receptor gene. J Neurosci 22: 92109220.
  • Balwierczak JL, Sharif R, Krulan CM, Field FP, Weiss GB, Miller MJ. 1991. Comparative effects of a selective adenosine A2 receptor agonist, CGS 21680, and nitroprusside in vascular smooth muscle. Eur J Pharmacol 196: 117123.
  • Bar-Yehuda S, Barer F, Volfsson L, Fishman P. 2001. Resistance of muscle to tumor metastases: A role for a3 adenosine receptor agonists. Neoplasia 3: 125131.
  • Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN. 2003. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61: 293296.
  • Belardinelli L, Shryock JC, Song Y, Wang D, Srinivas M. 1995. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. Faseb J 9: 359365.
  • Blum D, Galas MC, Pintor A, Brouillet E, Ledent C, Muller CE, Bantubungi K, Galluzzo M, Gall D, Cuvelier L, Rolland AS, Popoli P, Schiffmann SN. 2003. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: Implications for the neuroprotective potential of A2A antagonists. J Neurosci 23: 53615369.
  • Brackett LE, Daly JW. 1991. Relaxant effects of adenosine analogs on guinea pig trachea in vitro: Xanthine-sensitive and xanthine-insensitive mechanisms. J Pharmacol Exp Ther 257: 205213.
  • Brackett LE, Daly JW. 1994. Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. Biochem Pharmacol 47: 801814.
  • Brown R, Ollerstam A, Johansson B, Skott O, Gebre-Medhin S, Fredholm B, Persson AE. 2001. Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 281: R1362R1367.
  • Bunemann M, Pott L. 1995. Down-regulation of A1 adenosine receptors coupled to muscarinic K+ current in cultured guinea-pig atrial myocytes. J Physiol 482(Pt. 1): 8192.
  • Cass WA, Larson G, Fitzpatrick FA, Zahniser NR. 1991. Inhibitors of arachidonic acid metabolism: Effects on rat striatal dopamine release and uptake. J Pharmacol Exp Ther 257: 990996.
  • Cassada DC, Tribble CG, Long SM, Kaza AK, Linden J, Rieger JM, Rosin D, Kron IL, Kern JA. 2002. Adenosine A2A agonist reduces paralysis after spinal cord ischemia: Correlation with A2A receptor expression on motor neurons. Ann Thorac Surg 74: 846849; Discussion 849–850.
  • Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, Wierzbicki M, Verbeuren TJ, Cohen RA. 2001. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 21: 15771584.
  • Cerniway RJ, Yang Z, Jacobson MA, Linden J, Matherne GP. 2001. Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. Am J Physiol Heart Circ Physiol 281: H1751H1758.
  • Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA. 1999. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 91929200.
  • Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, Standaert DG, Aloyo VJ, Fink JS, Schwarzschild MA. 2000. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97: 195204.
  • Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, Ongini E, Schwarzschild MA. 2001a. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 98: 19701975.
  • Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Jr., Schwarzschild MA. 2001b. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21: RC143.
  • Chen J-F, Moratalla R, Yu L-Q, Ana B, Martín AB, Xu K, Bastia E, Hackett E, Israel Alberti I, Schwarzschild MA. 2003. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology 28: 10861095.
  • Collis MG, Brown CM. 1983. Adenosine relaxes the aorta by interacting with an A2 receptor and an intracellular site. Eur J Pharmacol 96: 6169.
  • Conti A, Monopoli A, Gamba M, Borea PA, Ongini E. 1993. Effects of selective A1 and A2 adenosine receptor agonists on cardiovascular tissues. Naunyn Schmiedebergs Arch Pharmacol 348: 108112.
  • Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. 1990. The adenosine/neutrophil paradox resolved: Human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest 85: 11501157.
  • Dall'lgna OP, Porciuncula LO, Souza DO, Cunha RA, Lara DR. 2003. Neuroprotection by caffeine and adenosine A(2A) receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138: 12071209.
  • Daly JW, Padgett WL. 1992. Agonist activity of 2- and 5′-substituted adenosine analogs and their N6-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to adenylate cyclase. Biochem Pharmacol 43: 10891093.
  • Daly JW, Butts-Lamb P, Padgett W. 1983. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines. Cell Mol Neurobiol 3: 6980.
  • Dart C, Standen NB. 1993. Adenosine-activated potassium current in smooth muscle cells isolated from the pig coronary artery. J Physiol 471: 767786.
  • Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L, Zoli M, Schiffmann SN. 2001. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 78: 183198.
  • Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, Schwarzschild MA, Fink JS, Linden J, Okusa MD. 2003. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 112: 883891.
  • Deckert J, Nothen MM, Bryant SP, Schuffenhauer S, Schofield PR, Spurr NK, Propping P. 1997. Mapping of the human adenosine A2a receptor gene: Relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum Genet 99: 326328.
  • Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. 1996. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 118: 14611468.
  • Dixon AK, Widdowson L, Richardson PJ. 1997. Desensitisation of the adenosine A1 receptor by the A2A receptor in the rat striatum. J Neurochem 69: 315321.
  • Dubey RK, Gillespie DG, Osaka K, Suzuki F, Jackson EK. 1996. Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. Hypertension 27(3 Pt. 2): 786793.
  • Dubey RK, Gillespie DG, Shue H, Jackson EK. 2000. A(2B) receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension 35(1 Pt. 2): 267272.
  • El Yacoubi M, Ledent C, Parmentier M, Daoust M, Costentin J, Vaugeois J. 2001. Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology 40: 424432.
  • Feoktistov I, Biaggioni I. 1995. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest 96: 19791986.
  • Feoktistov I, Biaggioni I. 1996. Role of adenosine in asthma. Drug Dev Res 39: 333336.
  • Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM. 1992. Molecular cloning of the rat A2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14: 186195.
  • Fishman P, Bar-Yehuda S, Farbstein T, Barer F, Ohana G. 2000a. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 adenosine receptors. J Cell Physiol 183: 393398.
  • Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Barer F, Multani AS. 2000b. Adenosine acts as an inhibitor of lymphoma cell growth: A major role for the A3 adenosine receptor. Eur J Cancer 36: 14521458.
  • Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS, Pathak S. 2001. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269: 230236.
  • Fredholm BB, Proctor W, Van der Ploeg I, Dunwiddie TV. 1989. In vivo pertussis toxin treatment attenuates some, but not all, adenosine A1 effects in slices of the rat hippocampus. Eur J Pharmacol 172: 249262.
  • Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. 2000. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 362: 364374.
  • Fuxe K, Ferre S, Zoli M, Agnati LF. 1998. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res Brain Res Rev 26: 258273.
  • Gao Z, Li BS, Day YJ, Linden J. 2001. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 59: 7682.
  • Gauthier NS, Headrick JP, Matherne GP. 1998. Myocardial function in the working mouse heart overexpressing cardiac A1 adenosine receptors. J Mol Cell Cardiol 30: 187193.
  • Goncalves J, Queiroz G. 1996. Purinoceptor modulation of noradrenaline release in rat tail artery: Tonic modulation mediated by inhibitory P2Y- and facilitatory A2A-purinoceptors. Br J Pharmacol 117: 156160.
  • Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. 2002. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105: 13481353.
  • Guo Y, Bolli R, Bao W, Wu WJ, Black RG, Jr., Murphree SS, Salvatore CA, Jacobson MA, Auchampach JA. 2001. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol 33: 825830.
  • Hasuo H, Shoji S, Gallagher JP, Akasu T. 1992. Adenosine inhibits the synaptic potentials in rat septal nucleus neurons mediated through pre- and postsynaptic A1-adenosine receptors. Neurosci Res 13: 281299.
  • Hauser RA, Hubble JP, Truong DD. 2003. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61: 297303.
  • Hettinger BD, Lee A, Linden J, Rosin DL. 2001. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431: 331346.
  • Higgins MJ, Hosseinzadeh H, MacGregor DG, Ogilvy H, Stone TW. 1994. Release and actions of adenosine in the central nervous system. Pharm World Sci 16: 6268.
  • Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, Franco R, Ferre S, Fuxe K. 2002. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277: 1809118097.
  • Iredale PA, Alexander SP, Hill SJ. 1994. Coupling of a transfected human brain A1 adenosine receptor in CHO-K1 cells to calcium mobilisation via a pertussis toxin-sensitive mechanism. Br J Pharmacol 111: 12521256.
  • Ito H, Vereecke J, Carmeliet E. 1994. Mode of regulation by G protein of the ATP-sensitive K+ channel in guinea-pig ventricular cell membrane. J Physiol 478(Pt. 1): 101107.
  • Ito H, Hosoya Y, Inanobe A, Tomoike H, Endoh M. 1995. Acetylcholine and adenosine activate the G protein-gated muscarinic K+ channel in ferret ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 351: 610617.
  • Jacobson KA, Nikodijevic O, Shi D, Gallo-Rodriguez C, Olah ME, Stiles GL, Daly JW. 1993. A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett 336: 5760.
  • Jacobson MA, Johnson RG, Luneau CJ, Salvatore CA. 1995. Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene. Genomics 27: 374376.
  • Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, Stiles GL, Ji XD. 1997. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology 36: 11571165.
  • Jain N, Kemp N, Adeyemo O, Buchanan P, Stone TW. 1995. Anxiolytic activity of adenosine receptor activation in mice. Br J Pharmacol 116: 21272133.
  • Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hardemark A, Betsholtz C, Herlenius E, Fredholm BB. 2001. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 98: 94079412.
  • Jones PA, Smith RA, Stone TW. 1998. Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience 85: 229237.
  • Jones MR, Zhao Z, Sullivan CP, Schreiber BM, Stone PJ, Toselli PA, Kagan HM, Cohen RA, Ravid K. 2004. A3 adenosine receptor deficiency does not influence atherogenesis. J Cell Biochem (in press).
  • Kirsch GE, Codina J, Birnbaumer L, Brown AM. 1990. Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 259(3 Pt. 2): H820H826.
  • Klapstein GJ, Colmers WF. 1992. 4-Aminopyridine and low Ca2+ differentiate presynaptic inhibition mediated by neuropeptide Y, baclofen and 2-chloroadenosine in rat hippocampal CA1 in vitro. Br J Pharmacol 105: 470474.
  • Kohno Y, Ji X, Mawhorter SD, Koshiba M, Jacobson KA. 1996a. Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 88: 35693574.
  • Kohno Y, Sei Y, Koshiba M, Kim HO, Jacobson KA. 1996b. Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A3 receptor agonists. Biochem Biophys Res Commun 219: 904910.
  • Le Poole IC, Yang F, Brown TL, Cornelius J, Babcock GF, Das PK, Boissy RE. 1999. Altered gene expression in melanocytes exposed to 4-tertiary butyl phenol (4-TBP): Upregulation of the A2b adenosine receptor 1. J Invest Dermatol 113: 725731.
  • Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388: 674678.
  • Linden J. 1994. Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 15: 298306.
  • Linden J. 2001. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775787.
  • Linden J, Taylor HE, Robeva AS, Tucker AL, Stehle JH, Rivkees SA, Fink JS, Reppert SM. 1993. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol Pharmacol 44: 524532.
  • Liu GS, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM. 1994. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 28: 10571061.
  • Londos C, Cooper DM, Wolff J. 1980. Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 77: 25512554.
  • MacCollin M, Peterfreund R, MacDonald M, Fink JS, Gusella J. 1994. Mapping of a human A2a adenosine receptor (ADORA2) to chromosome 22. Genomics 20: 332333.
  • Maggirwar SB, Dhanraj DN, Somani SM, Ramkumar V. 1994. Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res Commun 201: 508515.
  • Malhotra J, Gupta YK. 1997. Effect of adenosine receptor modulation on pentylenetetrazole-induced seizures in rats. Br J Pharmacol 120: 282288.
  • Marquardt DL, Walker LL, Heinemann S. 1994. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J Immunol 152: 45084515.
  • Martin PL. 1992. Relative agonist potencies of C2-substituted analogues of adenosine: Evidence for adenosine A2B receptors in the guinea pig aorta. Eur J Pharmacol 216: 235242.
  • Matherne GP, Linden J, Byford AM, Gauthier NS, Headrick JP. 1997. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci USA 94: 65416546.
  • Mayne M, Fotheringham J, Yan HJ, Power C, Del Bigio MR, Peeling J, Geiger JD. 2001. Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol 49: 727735.
  • Megson AC, Dickenson JM, Townsend-Nicholson A, Hill SJ. 1995. Synergy between the inositol phosphate responses to transfected human adenosine A1-receptors and constitutive P2-purinoceptors in CHO-K1 cells. Br J Pharmacol 115: 14151424.
  • Meng F, Xie GX, Chalmers D, Morgan C, Watson SJ, Jr., Akil H. 1994. Cloning and expression of the A2a adenosine receptor from guinea pig brain. Neurochem Res 19: 613621.
  • Merkel LA, Lappe RW, Rivera LM, Cox BF, Perrone MH. 1992. Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: Involvement of potassium channels. J Pharmacol Exp Ther 260: 437443.
  • Meyerhof W, Muller-Brechlin R, Richter D. 1991. Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett 284: 155160.
  • Mills I, Gewirtz H. 1990. Cultured vascular smooth muscle cells from porcine coronary artery possess A1 and A2 adenosine receptor activity. Biochem Biophys Res Commun 168: 12971302.
  • Mizumura T, Auchampach JA, Linden J, Bruns RF, Gross GJ. 1996. PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ Res 79: 415423.
  • Monopoli A, Lozza G, Forlani A, Mattavelli A, Ongini E. 1998. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9: 39553959.
  • Morrison RR, Jones R, Byford AM, Stell AR, Peart J, Headrick JP, Matherne GP. 2000. Transgenic overexpression of cardiac A(1) adenosine receptors mimics ischemic preconditioning. Am J Physiol Heart Circ Physiol 279: H1071H1078.
  • Naassila M, Ledent C, Daoust M. 2002. Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A2A receptors. J Neurosci 22: 1048710493.
  • Nakhostine N, Lamontagne D. 1993. Adenosine contributes to hypoxia-induced vasodilation through ATP-sensitive K+ channel activation. Am J Physiol 265(4 Pt. 2): H1289H1293.
  • Neary JT, McCarthy M, Kang Y, Zuniga S. 1998. Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. Neurosci Lett 242: 159162.
  • Neely CF, Keith IM. 1995. A1 adenosine receptor antagonists block ischemia-reperfusion injury of the lung. Am J Physiol 268(6 Pt. 1): L1036L1046.
  • Nie Z, Mei Y, Ramkumar V. 1997. Short term desensitization of the A1 adenosine receptors in DDT1MF-2 cells. Mol Pharmacol 52: 456464.
  • Nikodijevic O, Sarges R, Daly JW, Jacobson KA. 1991. Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: Evidence for synergism and antagonism. J Pharmacol Exp Ther 259: 286294.
  • Ohana G, Bar-Yehuda S, Barer F, Fishman P. 2001. Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor. J Cell Physiol 186: 1923.
  • Ohta A, Sitkovsky M. 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916920.
  • Okusa MD, Linden J, Macdonald T, Huang L. 1999. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol 277(3 Pt. 2): F404F412.
  • Okusa MD, Linden J, Huang L, Rieger JM, Macdonald TL, Huynh LP. 2000. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 279: F809F818.
  • Olivera A, Lopez-Novoa JM. 1992. Effect of adenosine and adenosine analogues on cyclic AMP accumulation in cultured mesangial cells and isolated glomeruli of the rat. Br J Pharmacol 107: 341346.
  • Olsson RA, Pearson JD. 1990. Cardiovascular purinoceptors. Physiol Rev 70: 761845.
  • Palmer TM, Stiles GL. 1995. Adenosine receptors. Neuropharmacology 34: 683694.
  • Palmer TM, Stiles GL. 1997a. Identification of an A2a adenosine receptor domain specifically responsible for mediating short-term desensitization. Biochemistry 36: 832838.
  • Palmer TM, Stiles GL. 1997b. Structure-function analysis of inhibitory adenosine receptor regulation. Neuropharmacology 36: 11411147.
  • Palmer TM, Benovic JL, Stiles GL. 1996. Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor. J Biol Chem 271: 1527215278.
  • Peakman MC, Hill SJ. 1994. Adenosine A2B-receptor-mediated cyclic AMP accumulation in primary rat astrocytes. Br J Pharmacol 111: 191198.
  • Peterfreund RA, MacCollin M, Gusella J, Fink JS. 1996. Characterization and expression of the human A2a adenosine receptor gene. J Neurochem 66: 362368.
  • Phillis JW. 1995. The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 705: 7984.
  • Piersen CE, True CD, Wells JN. 1994. A carboxyl-terminally truncated mutant and nonglycosylated A2a adenosine receptors retain ligand binding. Mol Pharmacol 45: 861870.
  • Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pezzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M. 2002. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22: 19671975.
  • Prentice DJ, Hourani SM. 1996. Activation of multiple sites by adenosine analogues in the rat isolated aorta. Br J Pharmacol 118: 15091517.
  • Puffinbarger NK, Hansen KR, Resta R, Laurent AB, Knudsen TB, Madara JL, Thompson LF. 1995. Production and characterization of multiple antigenic peptide antibodies to the adenosine A2b receptor. Mol Pharmacol 47: 11261132.
  • Ramkumar V, Olah ME, Jacobson KA, Stiles GL. 1991. Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells. Mol Pharmacol 40: 639647.
  • Ramkumar V, Stiles GL, Beaven MA, Ali H. 1993. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 268: 1688716890.
  • Ren H, Stiles GL. 1994. Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. J Biol Chem 269: 31043110.
  • Reppert SM, Weaver DR, Stehle JH, Rivkees SA. 1991. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol 5: 10371048.
  • Rivkees SA. 1994. Localization and characterization of adenosine receptor expression in rat testis. Endocrinology 135: 23072313.
  • Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease. Jama 283: 26742679.
  • Rubino A, Ralevic V, Burnstock G. 1993. The P1-purinoceptors that mediate the prejunctional inhibitory effect of adenosine on capsaicin-sensitive nonadrenergic noncholinergic neurotransmission in the rat mesenteric arterial bed are of the A1 subtype. J Pharmacol Exp Ther 267: 11001104.
  • Sakamoto J, Miura T, Goto M, Iimura O. 1995. Limitation of myocardial infarct size by adenosine A1 receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc Res 29: 682688.
  • Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. 1993. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 90: 1036510369.
  • Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. 2000. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275: 44294434.
  • Santicioli P, Del Bianco E, Maggi CA. 1993. Adenosine A1 receptors mediate the presynaptic inhibition of calcitonin gene-related peptide release by adenosine in the rat spinal cord. Eur J Pharmacol 231: 139142.
  • Schiffmann SN, Jacobs O, Vanderhaeghen JJ. 1991. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J Neurochem 57: 10621067.
  • Schwarzschild MA, Chen JF, Ascherio A. 2002. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 58: 11541160.
  • Stambaugh K, Jacobson KA, Jiang JL, Liang BT. 1997. A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia. Am J Physiol 273(1 Pt. 2): H501H505.
  • Stehle JH, Rivkees SA, Lee JJ, Weaver DR, Deeds JD, Reppert SM. 1992. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol Endocrinol 6: 384393.
  • Stoggall SM, Shaw JS. 1990. The coexistence of adenosine A1 and A2 receptors in guinea-pig aorta. Eur J Pharmacol 190: 329335.
  • Svenningsson P, Le Moine C, Fisone G, Fredholm BB. 1999. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 59: 355396.
  • Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, Fisone G. 2000. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 97: 18561860.
  • Szentmiklosi AJ, Ujfalusi A, Cseppento A, Nosztray K, Kovacs P, Szabo JZ. 1995. Adenosine receptors mediate both contractile and relaxant effects of adenosine in main pulmonary artery of guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 351: 417425.
  • Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, Koller BH. 2000. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. J Clin Invest 105: 361367.
  • Tucker AL, Jia LG, Holeton D, Taylor AJ, Linden J. 2000. Dominance of G(s) in doubly G(s)/G(i)-coupled chimaeric A(1)/A(2A) adenosine receptors in HEK-293 cells. Biochem J 352(Pt. 1): 203210.
  • van Calker D, Muller M, Hamprecht B. 1978. Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells. Nature 276: 839841.
  • van Calker D, Muller M, Hamprecht B. 1979. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33: 9991005.
  • Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Borea PA. 2000. [(3)H]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol 57: 968975.
  • Walker BA, Jacobson MA, Knight DA, Salvatore CA, Weir T, Zhou D, Bai TR. 1997. Adenosine A3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol 16: 531537.
  • Wang J, Drake L, Sajjadi F, Firestein GS, Mullane KM, Bullough DA. 1997. Dual activation of adenosine A1 and A3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 320: 241248.
  • Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L. 1999. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 10: 714720.
  • Yang Z, Cerniway RJ, Byford AM, Berr SS, French BA, Matherne GP. 2002. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol 282: H949H955.
  • Yao Y, Sei Y, Abbracchio MP, Jiang JL, Kim YC, Jacobson KA. 1997. Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem Biophys Res Commun 232: 317322.
  • Zahniser NR, Simosky JK, Mayfield RD, Negri CA, Hanania T, Larson GA, Kelly MA, Grandy DK, Rubinstein M, Low MJ, Fredholm BB. 2000. Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors. J Neurosci 20: 59495957.
  • Zhao Z, Francis CE, Ravid K. 1997. An A3-subtype adenosine receptor is highly expressed in rat vascular smooth muscle cells: Its role in attenuating adenosine-induced increase in cAMP. Microvasc Res 54: 243252.
  • Zhao Z, Makaritsis K, Francis CE, Gavras H, Ravid K. 2000. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice. Biochim Biophys Acta 1500: 280290.
  • Zhao Z, Yaar R, Ladd D, Cataldo LM, Ravid K. 2002. Overexpression of a3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. Microvasc Res 63: 6169.
  • Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, Civelli O. 1992. Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor. Proc Natl Acad Sci USA 89: 74327436.